Latest Brain tumor Stories

MADISON, Wisc., Nov. 5, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the closing of a private placement of equity securities to an affiliated entity of Renova Group for gross proceeds to Novelos of $2 million. The securities issued and sold in the private placement consisted of 2 million shares of Novelos' common stock, a warrant to purchase up to 1 million...

MADISON, Wis., Oct. 25, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center (UWCCC), a leading oncology research institution, has enrolled the first patient in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging agent, in patients with nine solid...

First image from a living animal wins 2012 Nikon Small World Competition that recognizes top photomicrographs from around the world MEMPHIS, Tenn., Oct. 23, 2012 /PRNewswire-USNewswire/ -- Among thousands of entries, Nikon has awarded its top honor to Jennifer Peters, Ph.D., and Michael Taylor, Ph.D., of St. Jude Children's Research Hospital for their photomicrograph, "The blood-brain barrier of a live zebrafish embryo." It is believed to be the first image showing the formation of...

Scientists have long believed that glioblastoma multiforme (GBM), the most aggressive type of primary brain tumor, begins in glial cells that make up supportive tissue in the brain or in neural stem cells. In a paper published October 18 in Science Express, however, researchers at the Salk Institute for Biological Studies have found that the tumors can originate from other types of differentiated cells in the nervous system, including cortical neurons. GBM is one of the most devastating...

Michael Harper for redOrbit.com – Your Universe Online It’s a debate nearly as old as cell phones themselves: Whether these mobile devices can cause brain tumors or if they pose no direct danger to humans. While study after study has been performed which proves and disproves both sides, an Italian court has taken it upon themselves to make an official ruling on the matter. According to Reuters, the Supreme Court of Italy has upheld a ruling which said one business executive’s...

Children who undergo brain radiation therapy run a significant risk of suffering from permanent neurocognitive adverse effects. These adverse effects are due to the fact that the radiation often encounters healthy tissue. This reduces the formation of new cells, particularly in the hippocampus – the part of the brain involved in memory and learning. Researchers at the University of Gothenburg's Sahlgrenska Academy have used a model study to test newer radiation therapy techniques which...

After leukaemia and brain tumors, neuroblastoma is the most common form of cancer to affect children. A thesis from the Sahlgrenska Academy, University of Gothenburg, Sweden, has studied a DNA method which is now used for all cases of neuroblastoma in Sweden, and which has led to more effective treatment at individual level. Neuroblastoma affects around 20 children each year, most of them under the age of two. This form of cancer, which affects the peripheral nervous system, is...

Describes how VISIUS(®) Surgical Theatre adds value in brain tumor management WINNIPEG, Oct. 10, 2012 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS) (TSX: IM) ("IMRIS" or the "Company") is announcing that the effective impact of high field strength intraoperative MRI (iMRI) for brain tumor management was the focus of the Congress of Neurological Surgeons (CNS) honored guest lecture. Dr. Ralph G. Dacey Jr., the current Henry G. and Edith R. Schwartz professor and chairman of the...

MADISON, Wis., Oct. 3, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that an oral presentation on research conducted by Jamey Weichert, Ph.D., Lance Hall, M.D., Anne M. Traynor, M.D., Glenn Liu, M.D. and their colleagues is being made by Dr. Weichert at the Imaging in 2020 Conference taking place September 30 to October 4, 2012 in Jackson Hole, Wyoming....

SEATTLE, Oct. 2, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced that OPAXIO (paclitaxel poliglumex) has been granted orphan-drug designation by the U.S Food and Drug Administration ("FDA") for the treatment of glioblastoma multiforme ("GBM"), a malignant brain cancer. Orphan designation was granted based on preliminary activity seen from phase 2 results of OPAXIO when added to standard therapy (temozolamide ("TMZ") plus radiation). In this...